
The development follows a letter sent by the country's apex drug regulator on Tuesday directing it to comply with "all" recommendations of an expert committee that looked into the matter.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2CpOJph
via
IFTTT
0 comments:
Post a Comment